Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial

NACompletedINTERVENTIONAL
Enrollment

672

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

January 1, 2024

Study Completion Date

July 30, 2025

Conditions
CancerAdvance Care Planning
Interventions
BEHAVIORAL

Facilitated advance care planning (in-person or telephonic)

The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.

BEHAVIORAL

Web-based advance care planning

Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Pittsburgh

OTHER

NCT03824158 - Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial | Biotech Hunter | Biotech Hunter